PREFUNDED COMMON STOCK PURCHASE WARRANT PROPANC BIOPHARMA, iNC.Propanc Biopharma, Inc. • April 3rd, 2020 • Pharmaceutical preparations
THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _________________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from Propanc Biopharma, Inc., a Delaware corporation (the “Company”), up to 10,445,482 shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). Notwithstanding anything herein to the contrary, all share numbers under this Warrant shall be subject to adjustment for reverse and forward stock splits and the like.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 3rd, 2020 • Propanc Biopharma, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of March 30, 2020, between Propanc Biopharma, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • April 3rd, 2020 • Propanc Biopharma, Inc. • Pharmaceutical preparations
This Registration Rights Agreement (this “Agreement”) is made and entered into as of March 30, 2020, between Propanc Biopharma, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • October 15th, 2019 • Propanc Biopharma, Inc. • Pharmaceutical preparations • New York
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of October 3, 2019, by and between PROPANC BIOPHARMA, INC., a Delaware corporation, with headquarters located at 302, 6 Butler Street, Camberwell, VIC, 3124 Australia (the “Company”), and CROWN BRIDGE PARTNERS, LLC, a New York limited liability company, with its address at 1173a 2nd Avenue, Suite 126, New York, NY 10065 (the “Buyer”).
COMMON STOCK PURCHASE WARRANT PROPANC HEALTH GROUP CORP.Propanc Health Group Corp • November 3rd, 2015 • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Delafield Investments Limited or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the four (4) year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Propanc Health Group Corp., a Delaware corporation (the “Company”), up to 26,190,476 shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 15th, 2023 • Propanc Biopharma, Inc. • Pharmaceutical preparations • Nevada
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of December 8, 2023, by and between PROPANC BIOPHARMA, INC., a Delaware corporation, with headquarters located at 302, 6 Butler Street, Camberwell, VIC 3124 Australia (the “Company”), and ONE44 CAPITAL LLC, a Nevada limited liability company, with its address at 1325 Airmotive Way Suite 202, Reno, NV 85902 (the “Buyer”).
COMMON STOCK PURCHASE WARRANT Propanc Biopharma, Inc.Common Stock Purchase Warrant • June 14th, 2019 • Propanc Biopharma, Inc. • Pharmaceutical preparations • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from Propanc Biopharma, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 7th, 2023 • Propanc Biopharma, Inc. • Pharmaceutical preparations • Virginia
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of November 29, 2023, by and between PROPANC BIOPHARMA, INC., a Delaware corporation, with its address at 302, 6 Butler Street, Camberwell, VIC, 3124 Australia (the “Company”), and 1800 DIAGONAL LENDING LLC, a Virginia limited liability company, with its address at 1800 Diagonal Road, Suite 623, Alexandria, VA 22314 (the “Buyer”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • July 26th, 2023 • Propanc Biopharma, Inc. • Pharmaceutical preparations
REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of July 20, 2023, by and between PROPANC BIOPHARMA, INC., a Delaware corporation (the “Company”), and DUTCHESS CAPITAL GROWTH FUND L.P., a Delaware limited partnership (together with it permitted assigns, the “Investor”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Common Stock Purchase Agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented, or otherwise modified from time to time, the “Purchase Agreement”).
10% PROMISSORY NOTEPropanc Biopharma, Inc. • May 15th, 2023 • Pharmaceutical preparations • Delaware
THIS IS A 10% PROMISSORY NOTE of Propanc Biopharma, Inc. (the “Company”), a Delaware Corporation, having its principal place of business at 302. 6 Butler Street, Camberwell, VIC 3124, Australia (this “Note”), which represents a duly authorized and validly issued debt of the Company.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • December 7th, 2016 • Propanc Health Group Corp • Pharmaceutical preparations • New York
This Registration Rights AGREEMENT (the “Agreement”), dated as of December 1, 2016 (the “Execution Date”), is entered into by and between Propanc Health Group Corporation, a Delaware corporation with its principal executive office at 302, 6 Butler Street Camberwell, VIC 3124 Australia (the “Company”), and GHS Investments LLC, a Nevada limited liability company, with offices at 200 Stonehinge Lane, Suite 3, Carle Place, NY 11514. (the “Investor”).
5% ORIGINAL ISSUE DISCOUNT SENIOR SECURED CONVERTIBLE DEBENTURE DUE september 13, 2017Propanc Health Group Corp • September 16th, 2016 • Pharmaceutical preparations • New York
THIS 5% ORIGINAL ISSUE DISCOUNT SENIOR SECURED CONVERTIBLE DEBENTURE of PROPANC HEALTH GROUP CORPORATION, a Delaware corporation, (the “Company”), having its principal place of business at 302, 6 Butler Street, Camberwell, VIC, 3124 Australia, designated as its 5% Original Issue Discount Senior Secured Convertible Debenture due September 13, 2017 (the “Debenture”).
COMMON STOCK PURCHASE WARRANT PROPANC BIOPHARMA, INC.Common Stock Purchase Warrant • September 9th, 2019 • Propanc Biopharma, Inc. • Pharmaceutical preparations • Delaware
This COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received (in connection with the issuance of the $550,000.00 convertible promissory note to the Holder (as defined below) of even date) (the “Note”), Auctus Fund, LLC, a Delaware limited liability company (including any permitted and registered assigns, the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date of issuance hereof, to purchase from Propanc Biopharma, Inc., a Delaware corporation (the “Company”), up to 225,000 shares of Common Stock (as defined below) (the “Warrant Shares”) (whereby such number may be adjusted from time to time pursuant to the terms and conditions of this Warrant) at the Exercise Price per share then in effect. This Warrant is issued by the Company as of the date hereof in connection with that certain securities purchase agreement dated August 30, 2019, by and among the Company
SECURITY AGREEMENTSecurity Agreement • September 29th, 2015 • Propanc Health Group Corp • Pharmaceutical preparations • New York
This SECURITY AGREEMENT, dated as of September 24, 2015 (this “Agreement”), is among Propanc Health Group Corp., a Delaware corporation (the “Company”), all of the Subsidiaries of the Company (such subsidiaries, the “Guarantors” and together with the Company, the “Debtors”) and the holder of the Company’s promissory note in the original aggregate principal amount of $1,200,000 (the “Debenture”) signatory hereto, its endorsees, transferees and assigns (collectively, the “Secured Parties”).
SERIES C COMMON STOCK PURCHASE WARRANT PROPANC BIOPHARMA, iNC.Propanc Biopharma, Inc. • April 3rd, 2020 • Pharmaceutical preparations
THIS SERIES C COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _________________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on the third anniversary of the date that the applicable Warrant Shares have vested pursuant to the Vesting Schedule (as defined below) (the “Termination Date”) but not thereafter, to subscribe for and purchase from Propanc Biopharma, Inc., a Delaware corporation (the “Company”), up to 63,750,000 shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. ;provided, however, the exercisability of this Series C Warrant shall vest ratably from time to time in proportion to the Holder’s (or its permitted assigns) exercise of the Series B Common Stock Purchase Warrant as compared with all Series B
EQUITY PURCHASE AGREEMENT BY AND BETWEEN PROPANC HEALTH GROUP CORPORATION AND SOUTHRIDGE PARTNERS II LP Dated July __, 2014Equity Purchase Agreement • September 22nd, 2014 • Propanc Health Group Corp • Pharmaceutical preparations • New York
THIS EQUITY PURCHASE AGREEMENT entered into as of the ___ day of February, 2014 (this "AGREEMENT"), by and between SOUTHRIDGE PARTNERS II LP, a Delaware limited partnership ("INVESTOR"), and PROPANC HEALTH GROUP CORPORATION, a Delaware corporation (the "COMPANY").
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • June 14th, 2019 • Propanc Biopharma, Inc. • Pharmaceutical preparations • New York
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • September 22nd, 2014 • Propanc Health Group Corp • Pharmaceutical preparations • New York
This Registration Rights Agreement ("Agreement"), dated July __, 2014, is made by and between PROPANC HEALTH GROUP CORPORATION, a Delaware corporation ("Company"), and SOUTHRIDGE PARTNERS II LP a Delaware limited partnership (the "Investor").
EQUITY PURCHASE AGREEMENTEquity Purchase Agreement • February 25th, 2019 • Propanc Biopharma, Inc. • Pharmaceutical preparations • Kansas
THIS EQUITY PURCHASE AGREEMENT (this “Agreement”) is entered into as of February 25, 2019 (the “Execution Date”), by and between Propanc Biopharma, Inc., a Delaware corporation (the “Company”), and Oasis Capital, LLC, a Puerto Rico limited liability company (the “Investor”).
EQUITY FINANCING AGREEMENTEquity Financing Agreement • December 7th, 2016 • Propanc Health Group Corp • Pharmaceutical preparations • New York
This EQUITY FINANCING AGREEMENT (the “Agreement”), dated as of December 1, 2016 (the “Execution Date”), is entered into by and between Propanc Health Group Corporation, a Delaware corporation with its principal executive office at 302, 6 Butler Street Camberwell, VIC 3124 Australia (the “Company”), and GHS Investments LLC, a Nevada limited liability company, with offices at 200 Stonehinge Lane, Suite 3, Carle Place, NY 11514. (the “Investor”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 15th, 2023 • Propanc Biopharma, Inc. • Pharmaceutical preparations • Delaware
THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of November 3, 2022 between Propanc Biopharma, Inc. a Delaware corporation (the “Company”), and Coventry Enterprises, LLC, a Delaware limited liability company (“Investor”).
COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • July 26th, 2023 • Propanc Biopharma, Inc. • Pharmaceutical preparations • Delaware
This Common Stock Purchase Agreement is entered into as of July 20, 2023 (this “Agreement”), by and between PROPANC BIOPHARMA, INC., a Delaware corporation (the “Company”), and DUTCHESS CAPITAL GROWTH FUND L.P., a Delaware limited partnership (the “Investor”). The Company and Investor may be referred to herein as each a “Party” and, collectively, the “Parties”.
SECURITY AGREEMENTSecurity Agreement • November 3rd, 2015 • Propanc Health Group Corp • Pharmaceutical preparations • New York
This SECURITY AGREEMENT, dated as of October __, 2015 (this “Agreement”), is among Propanc Health Group Corp., a Delaware corporation (the “Company”), all of the Subsidiaries of the Company (such subsidiaries, the “Guarantors” and together with the Company, the “Debtors”) and the holder of the Company’s 5% Original Issue Discount Senior Secured Convertible Debenture due twelve (12) months following its issuance, in the original aggregate principal amount of $4,400,000 (the “Debenture”) signatory hereto, its endorsees, transferees and assigns (collectively, the “Secured Parties”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • October 10th, 2018 • Propanc Biopharma, Inc. • Pharmaceutical preparations • Kansas
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of October 5, 2018 (the “Execution Date”), is entered into by and between PROPANC BIOPHARMA, INC., a Delaware corporation (the “Company”), and L2 CAPITAL, LLC, a Kansas limited liability company (together with its permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in that certain Equity Purchase Agreement by and between the parties hereto, dated as of the Execution Date (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).
CANCELLATION AGREEMENTCancellation Agreement • August 18th, 2021 • Propanc Biopharma, Inc. • Pharmaceutical preparations • Delaware
THIS CANCELLATION AGREEMENT (this “Agreement”), is entered into effective as of August 12, 2021, by and between Propanc Biopharma, Inc., a Delaware corporation (the “Company”) and Dr. Julian Kenyon,
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • November 1st, 2022 • Propanc Biopharma, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this“Agreement”) dated October 26, 2022, is made effective as of July 1, 2022 (the “Effective Date”) by and between Propanc Biopharma, Inc., a Delaware corporation (the “Company”), and James Nathanielsz (“Executive”). The Company and Executive sometimes are referred to herein collectively as the “Parties” and each individually as a “Party”. This Agreement is intended to and hereby amends and restates in its entirety that certain Employment Agreement between the Parties entered into on February 25, 2015, and as amended on April 14, 2016, September 25, 2017 and May 14, 2019.
5% ORIGINAL ISSUE DISCOUNT SENIOR SECURED CONVERTIBLE DEBENTURE DUE October 28, 2016Propanc Health Group Corp • November 3rd, 2015 • Pharmaceutical preparations • New York
THIS 5% ORIGINAL ISSUE DISCOUNT SENIOR SECURED CONVERTIBLE DEBENTURE of PROPANC HEALTH GROUP CORP., a Delaware corporation, (the “Company”), having its principal place of business at Level 2, 555 Riversdale Road, Cambwerwell, VIC, 3124 Australia, designated as its 5% Original Issue Discount Senior Secured Convertible Debenture due October 28, 2016 (the “Debenture”).
ContractPropanc Health Group Corp • April 13th, 2015 • Pharmaceutical preparations
THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. LENDERS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.
INDEMNIFICATION AGREEMENTIndemnification Agreement • December 30th, 2020 • Propanc Biopharma, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (this “Agreement”), dated as of December 23, 2020 and effective as of December 23, 2020 (the “Effective Date”), is made by and between Propanc Biopharma, Inc., a Delaware corporation (the “Company”), and Josef Zelinger (“Indemnitee”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • February 25th, 2019 • Propanc Biopharma, Inc. • Pharmaceutical preparations • Kansas
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of February 25, 2019 (the “Execution Date”), is entered into by and between PROPANC BIOPHARMA, INC., a Delaware corporation (the “Company”), and OASIS CAPITAL, LLC, a Puerto Rico limited liability company (together with its permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in that certain Equity Purchase Agreement by and between the parties hereto, dated as of the Execution Date (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).
Employment AgreementEmployment Agreement • March 25th, 2016 • Propanc Health Group Corp • Pharmaceutical preparations • Delaware
This Employment Agreement (the "Agreement") is made and entered into as of February 25th, 2015, by and between James Nathanielsz (the "Executive") and ProPanc Health Group Corporation, a Delaware Corporation (the "Company"), (collectively the “Parties”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 3rd, 2015 • Propanc Health Group Corp • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of October ___, 2015, between Propanc Health Group Corp., a Delaware corporation (the “Company”), and the purchaser identified on the signature pages hereto (including its successors and assigns, the “Purchaser”).
COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • May 15th, 2023 • Propanc Biopharma, Inc. • Pharmaceutical preparations • Delaware
This Common Stock Purchase Agreement (the “Agreement”) is entered into as of November 3, 2022, by and between PROPANC BIOPHARMA INC., a Delaware corporation (the “Company”), and COVENTRY ENTERPRISES, LLC, a Delaware limited liability company (the “Investor”). The Company and Investor may be referred to herein as each a ‘‘Party” and collectively, the “Parties”.
PROPANC BIOPHARMA, INC. AMENDED AND RESTATED DIRECTOR AGREEMENTDirector Agreement • August 18th, 2021 • Propanc Biopharma, Inc. • Pharmaceutical preparations • Delaware
This AMENDED AND RESTATED DIRECTOR AGREEMENT (this “Agreement”) by and between Josef Zelinger (“Director”) and Propanc Biopharma, Inc. (“Company”, and collectively, the “Parties”) is made effective on of August 12, 2021. This Agreement is intended to and hereby amends and restates in its entirety that certain Director Agreement between the Parties entered into as of December 23, 2020 (the “Appointment Date”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 15th, 2023 • Propanc Biopharma, Inc. • Pharmaceutical preparations • Delaware
This Registration Rights Agreement (this “Agreement”), dated as of November 3, 2022, by and between PROPANC BIOPHARMA, INC., a Delaware corporation (the “Company”), and Coventry Enterprises, LLC, a Delaware limited liability company (together with it permitted assigns, the “Investor”) (the Company and Investor each a “Party” and together the “Parties”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Common Stock Purchase Agreement by and between the Parties, dated as of the date hereof (as amended, restated, supplemented, or otherwise modified from time to time, the “Purchase Agreement”).
